Sort   by:  
 Page size 
UnknownHealth-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Not available
S-EPMC5791840 | biostudies-literature
UnknownMolecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.
Not available
S-EPMC6369924 | biostudies-literature
TranscriptomicsLudwig Institute/UCSD ENCODE project June 2007 Release
The readout of genome information is controlled by transcriptional regulatory elements, but a comprehensive view of the combinatorial control by these DNA sequences, which bind regulatory protein and/or the modified histones in regulating gene transcription, is clearly preliminary. We have developed...
ORGANISM(S): Homo sapiens 
2007-06-01 | E-GEOD-7872 | biostudies-arrayexpress
TranscriptomicsCereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [expression profiling]
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their anti-tumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the anti-myeloma activity of IMiDs....
ORGANISM(S): Homo sapiens 
2011-09-30 | E-GEOD-31421 | biostudies-arrayexpress
TranscriptomicsCereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [aCGH]
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their anti-tumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the anti-myeloma activity of IMiDs....
ORGANISM(S): Homo sapiens 
2011-09-30 | E-GEOD-31451 | biostudies-arrayexpress
UnknownRegistry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance.
Not available
S-EPMC7328667 | biostudies-literature
UnknownPharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Not available
S-EPMC3951913 | biostudies-literature
UnknownMass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.
Not available
S-EPMC10203138 | biostudies-literature
GenomicsGenome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing

In this study, we whole genome sequenced tumor/normal pairs from three pancreatic adenocarcinoma patients to separately characterize each patient with respect to somatic alterations. For 2 patients for whom tumor RNA was available, we also performed RNA sequencing to evaluate gene expression chan...

phs000550.v1.p1 | EGA
Genomicsena-DATASET-MUGQIC-21-03-2014-16:25:00:707-841 - samples
Exome sequencing of familial and sporadic small cell cancer of ovary cases.
EGAD00001000791 | EGA
Sort   by:  
 Page size